1. Home
  2. HTCR vs CMMB Comparison

HTCR vs CMMB Comparison

Compare HTCR & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heartcore Enterprises Inc.

HTCR

Heartcore Enterprises Inc.

N/A

Current Price

$0.25

Market Cap

6.5M

Sector

Technology

ML Signal

N/A

Logo Chemomab Therapeutics Ltd.

CMMB

Chemomab Therapeutics Ltd.

N/A

Current Price

$1.95

Market Cap

9.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HTCR
CMMB
Founded
2009
2004
Country
Japan
Israel
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
9.1M
IPO Year
2022
2023

Fundamental Metrics

Financial Performance
Metric
HTCR
CMMB
Price
$0.25
$1.95
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
362.4K
68.7K
Earning Date
05-22-2026
01-01-0001
Dividend Yield
51.18%
N/A
EPS Growth
66.67
101.67
EPS
N/A
0.04
Revenue
$30,407,229.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.52
N/A
P/E Ratio
N/A
$49.25
Revenue Growth
39.19
N/A
52 Week Low
$0.22
$0.87
52 Week High
$1.66
$3.86

Technical Indicators

Market Signals
Indicator
HTCR
CMMB
Relative Strength Index (RSI) 45.11 60.10
Support Level $0.25 $1.48
Resistance Level $0.30 $2.24
Average True Range (ATR) 0.03 0.18
MACD 0.00 0.05
Stochastic Oscillator 31.30 91.91

Price Performance

Historical Comparison
HTCR
CMMB

About HTCR Heartcore Enterprises Inc.

HeartCore Enterprises Inc is a software development company. The company provides software through two business units. The first business unit includes a customer experience management business. The customer experience management platform includes marketing, sales, service, and content management systems, as well as other tools and integrations that enable companies to attract and engage customers throughout the customer experience. It also provides education, services and support to help customers be successful with the CXM Platform. The second business unit, DX division, is a digital transformation business that provides customers with robotics process automation, process mining, and task mining to accelerate the digital transformation of enterprises.

About CMMB Chemomab Therapeutics Ltd.

Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.

Share on Social Networks: